Extrapulmonary Small Cell Carcinoma

Shahab, Nasir; Mirza, Irfan Ali; Doll, Donald C.

doi:10.1053/j.seminoncol.2006.10.023

Cited by 11 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EPSCC accounts for less than 0.4% of all cancers [9,30,31,36]. EPSCC has been described in almost all organs, including the central nervous system [6,10,30,31].…”

Section: Discussionmentioning

confidence: 99%

Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation?

Früh

Ess

et al. 2011

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…EPSCC accounts for less than 0.4% of all cancers [9,30,31,36]. EPSCC has been described in almost all organs, including the central nervous system [6,10,30,31].…”

Section: Discussionmentioning

confidence: 99%

Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation?

Früh

Ess

et al. 2011

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…4 Small cell carcinomas in general are now believed to originate from totipotential stem cells that can differentiate into various cell types that are native to the tissues, eg, TTF-1-positive stem cell for pulmonary small cell carcinoma. 3 This hypothesis may explain occasional cases of small cell carcinoma with other components such as squamous cell carcinoma 17 and adenocarcinoma, 18 the findings described in a variety of organs including skin and lung. [17][18][19][20] Cutaneous metastasis of visceral carcinomas is usually an expression of the disseminated disease.…”

Section: Discussionmentioning

confidence: 99%

“…2,3 It is currently recommended that patients be screened for small cell carcinoma of the lung to exclude the possibility of cutaneous metastasis of small cell carcinoma once a diagnosis of cutaneous Merkel cell carcinoma is made, illustrating the importance of determining reliable pathological markers to distinguish these lesions. 4 Small cell carcinomas in general are now believed to originate from totipotential stem cells that can differentiate into various cell types that are native to the tissues, eg, TTF-1-positive stem cell for pulmonary small cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…2,3 It is morphologically very similar to small cell carcinomas of the lung and other organs, 3 and its diagnosis requires confirmation by immunohistochemistry study, in conjunction with careful clinical and radiographic information, to rule out a metastatic small cell carcinoma, particularly from the lung. 4 Achaete-scute complex-like 1 (ASCL1), also called mammalian or human achaetescute complex homolog-1 (MASH1, HASH1), is a basic helix-loop-helix transcription factor crucial for neuroendocrine cell differentiation.…”

mentioning

confidence: 99%

See 1 more Smart Citation

MASH1: a useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma

2008

View full text Add to dashboard Cite

Merkel cell carcinoma is the cutaneous counterpart of small cell carcinoma, and the most important differential diagnosis is cutaneous metastasis of small cell carcinoma of the lung. There have been a handful of studies reporting on the utility of a variety of immunohistochemical markers that distinguish between the two entities. Achaete-scute complex-like 1 (MASH1, ASCL1) is important in the development of the brain and the diffuse neuroendocrine system including pulmonary neuroendocrine cells. A recent study, using a cDNA array, identified Mash1 as one of the best classifier genes to differentiate pulmonary small cell carcinoma from Merkel cell carcinoma. We immunohistochemically applied this finding to the diagnostic setting. A total of 30 cases of Merkel cell carcinoma and 59 cases of small cell carcinoma of the lung were immunostained with anti-MASH1 and TTF-1 antibodies. Of 59 small cell carcinomas, 49 (83%) expressed MASH1 in nuclear staining whereas out of 59 small cell carcinomas, 43 (73%) expressed TTF-1 in nuclear staining. MASH1 was completely negative in all 30 Merkel cell carcinomas whereas TTF-1 expression was seen in 1 of the 30 Merkel cell carcinomas (3%). MASH1 is a useful adjunct marker for differentiating small cell carcinoma of the lung from Merkel cell carcinoma.

show abstract

“…EPSCC is known to involve gastrointestinal tract (esophagus, stomach, liver, bile ducts, intestines and pancreas) [3][4][5] , genitourinary tract (kidney, ureter, pelvis, bladder) [6][7][8][9][10] , head and neck region (tonsils, larynx, nasopharynx, and paranasal sinuses) [11][12][13][14] , bones [15] and lymph nodes (locoregional or distant) [16][17][18][19][20][21][22][23] . Although, EPSCC has histological similarity with small cell lung cancer, it has a different biological behaviour [1,24,25] . Also, the biological behaviour varies with the site of origin and the extent of the cancer.…”

Section: Introductionmentioning

confidence: 99%

Extrapulmonary small cell carcinoma of lymph node: Pooled analysis of all reported cases

Sehgal¹,

Kaur²,

Dhooria³

et al. 2016

WJCO

View full text Add to dashboard Cite

AIM:To study clinical outcomes and management of lymph nodes extrapulmonary small cell carcinoma (LNEPSCC). METHODS:Herein, we perform a systematic search of published literature in the PubMed and EMBASE databases for studies describing LNEPSCC. For uniformity of reporting, LNEPSCC was staged as limited if it involved either single lymph node station or if surgery with curative intent had been undertaken. The disease was staged extensive if it involved two or more lymph node regions. RESULTS:The systematic literature review yielded eight descriptions (n = 14) involving cervical, submandibular and inguinal lymph nodes. Eleven (64.7%) patients had limited disease (LD) and six (35.3%) had extensive disease (ED) at presentation. Chemotherapy (n = 6, 35.3%) or surgery (n = 4, 23.5%) were the most common form of treatment given to these patients. Complete response was achieved in 12 (70.6%) of the patients. Median (interquartile range) progression free survival and overall survival was 15 (7-42) mo and 22 (12.75-42) mo respectively. Of the three illustrative cases, two patients each had ED at presentation and achieved complete remission with platinum based combination chemotherapy.

show abstract

Extrapulmonary Small Cell Carcinoma

Cited by 11 publications

References 13 publications

Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation?

Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation?

MASH1: a useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma

Extrapulmonary small cell carcinoma of lymph node: Pooled analysis of all reported cases

Contact Info

Product

Resources

About